Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung cancer that has specific epidermal growth factor receptor mutations.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
